Brief: Vivesto Announces Positive Preclinical Results For Cantrixil In AML
04/11/2025 07:03
Nov 4 (Reuters) - Vivesto AB VIVE.ST: ANNOUNCES POSITIVE PRECLINICAL RESULTS FOR CANTRIXIL IN AML Source text: ID:nMFN4w9xSx Further company coverage: VIVE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Vivesto AB
See all newsBrief: Vivesto Reports Positive Topline Results From Paccal Vet Study In Cats
Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
Brief: Vivesto Q2 Operating Loss At SEK 8.6 Mln
Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
Brief: Vivesto Appoints Björn Svanström As CFO